{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:39:38Z","timestamp":1793342378617,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["T-B-081"],"award-info":[{"award-number":["T-B-081"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2023-I2M-C"],"award-info":[{"award-number":["2023-I2M-C"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172875"],"award-info":[{"award-number":["82172875"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","award":["2022-I2M-2-001"],"award-info":[{"award-number":["2022-I2M-2-001"]}],"id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.breast.2025.104470","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T06:06:55Z","timestamp":1743919615000},"page":"104470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["The ideal strategies of antibody\u2012drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: A multi-center real-world study"],"prefix":"10.1016","volume":"81","author":[{"given":"Xuenan","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2962-439X","authenticated-orcid":false,"given":"Bo","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongnan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruigang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9432-1902","authenticated-orcid":false,"given":"Fei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.breast.2025.104470_bib1","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.breast.2025.104470_bib2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2025.104470_bib3","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Di\u00e9ras","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.breast.2025.104470_bib4","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.breast.2025.104470_bib5","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.breast.2025.104470_bib6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/cac2.12577","article-title":"Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I\/Ib study","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun"},{"issue":"1","key":"10.1016\/j.breast.2025.104470_bib7","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1038\/s41467-024-48798-w","article-title":"HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a\/1b trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"issue":"16_suppl","key":"10.1016\/j.breast.2025.104470_bib8","volume":"41","author":"Ma","year":"2023","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.breast.2025.104470_bib9","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1200\/JCO.2011.40.5902","article-title":"A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine","volume":"30","author":"Krop","year":"2012","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.breast.2025.104470_bib10","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.breast.2025.104470_bib11","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1200\/JCO.19.02318","article-title":"Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study","volume":"38","author":"Modi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2025.104470_bib12","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/annonc\/mdr444","article-title":"A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer","volume":"23","author":"Aogi","year":"2012","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.breast.2025.104470_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"17_suppl","key":"10.1016\/j.breast.2025.104470_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1000","volume":"42","author":"Curigliano","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104470_bib15","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.breast.2025.104470_bib16","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104470_bib17","doi-asserted-by":"crossref","first-page":"S635","DOI":"10.1016\/j.annonc.2022.07.253","article-title":"214MO Sacituzumab govitecan (SG) efficacy in hormone receptor-positive\/human epidermal growth factor receptor 2-negative (HR+\/HER2\u2013) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study","volume":"33","author":"Schmid","year":"2022","journal-title":"Ann Oncol"},{"issue":"9_Supplement","key":"10.1016\/j.breast.2025.104470_bib18","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PS08-03","article-title":"Abstract PS08-03: sequencing antibody-drug conjugate after antibody-drug conjugate in metastatic breast cancer (A3 study): multi-institution experience and biomarker analysis","volume":"84","author":"Abelman","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2025.104470_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-024-02766-9","article-title":"Efficacy of administration sequence: sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer","author":"Poumeaud","year":"20241314702","journal-title":"Br J Cancer"},{"issue":"16_suppl","key":"10.1016\/j.breast.2025.104470_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.1083","volume":"42","author":"Huppert","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.breast.2025.104470_bib21","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.breast.2025.104470_bib22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.trecan.2019.12.010","article-title":"Trastuzumab emtansine: mechanisms of action and resistance, clinical progress, and beyond","volume":"6","author":"Garc\u00eda-Alonso","year":"2020","journal-title":"Trends in cancer"},{"issue":"7","key":"10.1016\/j.breast.2025.104470_bib23","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"issue":"7","key":"10.1016\/j.breast.2025.104470_bib24","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody\u2013drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.breast.2025.104470_bib25","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.breast.2025.104470_bib26","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1158\/1535-7163.MCT-17-0296","article-title":"Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells","volume":"17","author":"Li","year":"2018","journal-title":"Mol Cancer Therapeut"},{"issue":"3","key":"10.1016\/j.breast.2025.104470_bib27","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cac2.12387","article-title":"Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions","volume":"43","author":"Chen","year":"2023","journal-title":"Cancer Commun"},{"issue":"7_Supplement","key":"10.1016\/j.breast.2025.104470_bib28","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-383","article-title":"Abstract 383: trastuzumab deruxtecan resistance is associated with reduced responsiveness to topoisomerase inhibitors (payload resistance) but no reduction in sensitivity to HER2 tyrosine kinase inhibitors","volume":"83","author":"Nilsson","year":"2023","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.breast.2025.104470_bib29","doi-asserted-by":"crossref","first-page":"e957","DOI":"10.1093\/oncolo\/oyae055","article-title":"Optimal sequential strategies for antibody-drug conjugate in metastatic breast cancer: evaluating efficacy and cross-resistance","volume":"29","author":"Chen","year":"2024","journal-title":"Oncologist"},{"issue":"17","key":"10.1016\/j.breast.2025.104470_bib30","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-Low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.breast.2025.104470_bib31","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.breast.2025.104470_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096993","article-title":"Trop-2 is a determinant of breast cancer survival","volume":"9","author":"Ambrogi","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.breast.2025.104470_bib33","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10549-022-06660-x","article-title":"Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer","volume":"194","author":"Vidula","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2025.104470_bib34","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1158\/1535-7163.MCT-22-0375","article-title":"Antibody-drug conjugate sacituzumab govitecan drives efficient tissue penetration and rapid intracellular drug release","volume":"22","author":"Kopp","year":"2023","journal-title":"Mol Cancer Therapeut"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625004874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625004874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T02:52:31Z","timestamp":1763607151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977625004874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":34,"alternative-id":["S0960977625004874"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2025.104470","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The ideal strategies of antibody\u2012drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: A multi-center real-world study","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2025.104470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104470"}}